The Study Of Thalidomide Affecting VEGF Of Non-Hodgkin Lymphoma Raji Cells

Objective: In recent years, vascular endothelial growth factor (VEGF) as the key factor promoted angiogenesis, the research of its effects is progressing rapidly in the pathophysiology and development mechanism of malignancies . Thalidomide , known as its antiangiogenic properties has shown clinical activity in non-Hodgkin lymphoma. But the specific mechanism is not fully appreciated. This study focused on thalidomide affecting VEGF of non-Hodgkin lymphoma Raji cell lines in vitro, and approached the mechanism of action.Methods: The MTT method was applied to study the growth inhibition of Raji cells treated with thalidomide . The ELISA method was applied to study VEGF contents in cultured supernatants of Raji cells treated with different concentrations of thalidomide in different time points.Results: Thalidomide showed no direct inhibition in the Raji cells growth(p>0.05) in MTT method. In ELISA method different concentrations of thalidomide such as 5μg/ml, 10μg/ml, 25μg/ml, 50μg/ml affected the contents of VEGF in Raji cells supernatant, the results showed: 10μg/ml, 25μg/ml, 50μg/ml of thalidomide groups inhibited VEGF secretion significantly (p<0.05), except the 5μg/ml and DMSO controls (P>0.05). Thalidomide on Raji cells inhibited secretion of VEGF in a dose-dependent manner and a time-dependent manner.Conclusions: Thalidomide could inhibit VEGF secretion of non-Hodgkin lymphoma Raji cells in vitro. Thalidomide induced the inhibition of VEGF was in a dose-dependent manner and time-dependent manner. Thalidomide had no direct and obvious anti-proliferation effect and cytotoxic activity on Raji cells.